论文部分内容阅读
目的:观察施他宁(生长抑素)治疗支气管扩张并咯血的临床疗效。方法:选取我院2009年1月—2010年12月收治的支气管扩张并咯血的患者64例随机分为治疗组和对照组各32例,治疗组开始先静推250μg(3～5min内),继以250μg/h静滴,止血后应连续给药72h;对照组以垂体后叶素5μg稀释后缓慢静注,继以20μg加入5%葡萄糖250mL静滴。比较两组患者临床疗效。结果:治疗组中显效22例,有效8例,无效2例,总有效率为93.75%;对照组中显效18例,有效4例,无效2例,总有效率为68.75%,P<0.05,差异具有统计学意义。从临床不良反应来看,治疗过程中治疗组腹痛发生11例,发热1例,休克8例,心悸8例,眩晕2例,总计发生不良临床反应22例,发生率为62.48%;对照组腹痛18例,发热12例,恶心15例,心悸10例,眩晕3例,耳鸣3例,不良反应发生率为190.83%,两组比较差异具有统计学意义(P<0.05)。结论:施他宁治疗支气管扩张并咯血效果理想,值得临床推广使用。
Objective: To observe the clinical efficacy of Sitatin (somatostatin) in the treatment of bronchiectasis and hemoptysis. Methods: Sixty-four patients with bronchiectasis and hemoptysis admitted to our hospital from January 2009 to December 2010 were randomly divided into treatment group (32 cases) and control group (32 cases). The treatment group started to push 250 μg (within 3-5 minutes) Subsequent to 250μg / h intravenous infusion, bleeding should be continuous after 72h; control group to pituitrin 5μg diluted intravenous infusion, followed by 20μg added 5% glucose 250mL intravenous infusion. The clinical efficacy of the two groups was compared. Results: In the treatment group, 22 cases were markedly effective, 8 cases were effective, 2 cases were ineffective, and the total effective rate was 93.75%. In the control group, 18 cases were markedly effective, 4 cases were effective and 2 cases were ineffective. The total effective rate was 68.75% The difference was statistically significant. In terms of clinical adverse reactions, 11 cases of abdominal pain, 1 case of fever, 8 cases of shock, 8 cases of heart palpitations and 2 cases of dizziness occurred in the treatment group and 22 cases of adverse clinical reactions, the incidence rate was 62.48%. In the control group, abdominal pain 18 cases, fever in 12 cases, nausea in 15 cases, heart palpitations in 10 cases, vertigo in 3 cases, tinnitus in 3 cases, the incidence of adverse reactions was 190.83%, the difference between the two groups was statistically significant (P <0.05). Conclusion: Sitatin treatment of bronchiectasis and hemoptysis ideal, worthy of clinical promotion.